Molsidomine

As a classic anti-angina cardiovascular drug, molsidomine is a derivative of calcium channel blocker. It can relax vascular smooth muscle by releasing nitric oxide, reduce the preload and afterload of the heart and myocardial oxygen consumption, and dilate coronary arteries to improve myocardial blood supply. It is mainly used clinically to prevent angina pectoris attacks, and can also be used for symptom control in patients with myocardial infarction accompanied by pulmonary hypertension. The applicable population covers adult patients with long-term management of chronic coronary heart disease and recurrent angina pectoris. It has long-lasting efficacy and good tolerance, and is an important part of the primary cardiovascular disease medication system.

At present, the global market size of molsidomine is about USD 120 million. In recent years, affected by the rising prevalence of chronic diseases and the release of primary medication demand, the compound annual growth rate has remained at around 3.2%. The domestic market is dominated by generic drug supply. Due to its affordable price and mature clinical pathway, the purchase volume of primary medical institutions accounts for more than 65%. In 2023, the overall market size was about RMB 180 million. After the implementation of centralized procurement, the price of relevant generic drugs dropped by 42%, further improving patient accessibility. There are less than 10 existing manufacturers, and the market competition pattern is relatively stable.

The original research enterprise of molsidomine is Bayer Pharma AG, Germany, with the original brand name Corvaton, and the core compound patent expired globally in 1982. The main dosage form approved for the original drug is tablet, with specifications of 1mg and 2mg. The original preparation has been included in the FDA Orange Book Reference Listed Drug Catalog, and has not been included in the Chinese Reference Listed Drug Catalog at present. There is no original preparation approved for marketing in China. There are 3 registered API manufacturers, all of which are domestic local manufacturers, holding 4 API registration numbers with A status. The corresponding approved preparation varieties are mainly tablets, and a small number of aerosol dosage forms are also approved. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for molsidomine API. Most products support spot supply. Spot orders placed before 16:00 can be shipped on the same day. All products meet the requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can fully meet the use needs of different scenarios such as API R&D, quality research and consistency evaluation.